Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Date:4/21/2009

gression-free survival data at the 2009 American Society of Clinical Oncology Annual Meeting."

The picoplatin data were presented today in a poster session (abstract #3578) during the American Association for Cancer Research's 100th Annual Meeting 2009 at the Colorado Convention Center in Denver. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent in clinical development to treat multiple types of cancer. It is designed to overcome platinum resistance associated with chemotherapy in solid tumors.

Phase 1 CRC Study Design and Results

In the Phase 1 study, 73 patients received the FOLPI regimen with picoplatin administered either every two or every four weeks to evaluate safety and identify the maximum tolerated dose and the optimal schedule of FOLPI administration. Patients received a total picoplatin exposure of between 85 mg/m squared and 1,871 mg/m squared.

None of the patients who received picoplatin exhibited severe neuropathy (Grade 3 or 4), as is commonly seen in metastatic CRC patients treated with the FOLFOX regimen at cumulative oxaliplatin doses above 800 mg/m squared. In addition, none of the patients who received picoplatin exhibited severe (Grade 3/4) nephrotoxicity (kidney toxicity) or ototoxicity (hearing toxicity).

The dose limiting toxicities for both the every-four-week regimen and the every-two-week regimen were neutropenia and thrombocytopenia, which were reversible. The maximum tolerated dose of picoplatin in the every-four-week FOLPI schedule was 150 mg/m squared. 150 mg/m squared for the every-four-week FOLPI schedule and 85 mg/m squared for the every-two-week FOLPI schedule achieved 80 percent of the planned dose and support further clinical studies at these doses and schedules. The 150 mg/m squared dose and schedule was selected for evaluation in the ongoing randomized Phase 2 trial.

'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
2. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
3. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
4. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
5. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
8. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
9. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
10. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
11. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... the Hill, Advocates in Washington, D.C. with Online Supporters ... Colitis Foundation of America (CCFA) and Shire plc (LSE: ... launch the first-ever virtual "Inflammatory Bowel Disease (IBD) March ... users to help raise awareness of IBD and spurs ...
... MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is ... 2a, proof-of-concept, clinical trial for AEG33773, a novel, ... market of painful diabetic neuropathy. , The Phase ... Study Comparing the Safety and Efficacy of AEG33773 ...
... Pierre Fabre Dermatologie,specialised department of Pierre Fabre Laboratories, ... of clinical trials following the signature of an ... with the University of,Bordeaux. The contract covers the ... the treatment of severe infantile haemangioma,with the intention ...
Cached Biology Technology:The Crohn's & Colitis Foundation of America and Shire Launch Virtual 'IBD March on the Hill' to Increase Funding for Digestive Disease Research 2The Crohn's & Colitis Foundation of America and Shire Launch Virtual 'IBD March on the Hill' to Increase Funding for Digestive Disease Research 3The Crohn's & Colitis Foundation of America and Shire Launch Virtual 'IBD March on the Hill' to Increase Funding for Digestive Disease Research 4Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma 2
(Date:4/17/2014)... a word for chili peppers. Information about archaeological remains ... study of the appearance of words for chili peppers ... were domesticated and highlight the value of multi-proxy data ... al.) of nine papers presented in a special feature ... of Sciences on plant and animal domestication edited ...
(Date:4/17/2014)... 2014. Kessler Foundation has been named awardee of ... Department of Defense Spinal Cord Injury Research Program. ... the randomized, double-blinded, controlled, multi-site clinical trial, which ... strength after spinal cord injury. Dr. Forrest is ... at Kessler Foundation. Two additional sites will participate ...
(Date:4/17/2014)... Andr Gauthier and Professor Luca Razzari of the ... awarded large grants from the John R. Evans ... (CFI) for the acquisition of state-of-the-art biotech and ... matching grants from the Ministre de l,Enseignement suprieur, ... la Technologie (MESRST). These new laboratories will help ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2New state-of-the-art biotech and nanotech equipment for INRS 2
... from Australia and the United States bring new insights to ... of the biggest challenges currently facing the fields of genomics ... , online today. Roughly 3 metres of DNA is ... body. This folding allows some genes to be ,expressed, or ...
... group of synthetic proteins called CRISPR-Cas RNA-guided nucleases (RGNs) ... gene-editing tools. Exploiting a method that some bacteria use ... cut through DNA strands at specific sites, allowing the ... of Massachusetts General Hospital (MGH) researchers has found a ...
... invades rice crops around the world, killing plants and cutting production ... a study by an international team of researchers has shed light ... plant tissue. The finding is a step toward learning how to ... feed 60 million people annually. The team, led ...
Cached Biology News:The genome's 3-D structure shapes how genes are expressed 2Powerful gene-editing tool appears to cause off-target mutations in human cells 2Powerful gene-editing tool appears to cause off-target mutations in human cells 3Scientists discover new details about rice blast, a deadly plant fungus 2
... been designed and created in order to ... genotyping analysis tool. We incorporated the suggestions ... the software. Their main requirements were ease- ... acquisition cost. GeneMarker can perform analysis ...
These stopping screens are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 screens....
... multi-functional program that searches for ... sequence file for polymerase chain ... mutagenesis, and various hybridization applications. ... secondary structure of oligonucleotides based ...
... Expression is a revolutionary new application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
Biology Products: